secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001641172-25-020802
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics appoints Timothy R. Wright as Class II director
-----------------------------------------------------------------------

- Timothy R. Wright appointed to board effective July 18, 2025 as Class II director, term expires at 2026 annual meeting.
- Board determined Wright is independent under Nasdaq rules; board now has three independent directors.
- Wright is Executive Chairman of Isosceles (since 2019) and President/CEO of BIORG, INC. (since 2023).
- He also serves on the board of Agenus Inc. (since 2006) and previously held executive roles at Covidien/Medtronic and Teva.
- Wright will receive standard non-employee director compensation as described in the January 2025 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225020802/0001641172-25-020802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225020802/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-020802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer